A Phase II Study of Pegylated Liposomal Doxorubicin (Lipo-Dox) Combined With Cyclophosphamide /5-Fluorouracil as Second Line Chemotherapy in the Treatment of Metastatic Breast Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Hsien-Kun Chang
Principal Investigator
Chang Gung Memorial Hospital, Lin-Kou Medical Center
Taiwan: Department of Health
LD0411
NCT01451580
September 2005
Name | Location |
---|